Genomic Profiling of Penile Squamous Cell Carcinoma Reveals New Opportunities for Targeted Therapy

• Published in: Cancer research (Chicago, Ill.) Ill.), 2015-12, Vol.75 (24), p.5219-5227
• Main Authors: McDaniel, Andrew S, Hovelson, Daniel H, Cani, Andi K, Liu, Chia-Jen, Zhai, Yali, Zhang, Yajia, Weizer, Alon Z, Mehra, Rohit, Feng, Felix Y, Alva, Ajjai S, Morgan, Todd M, Montgomery, Jeffrey S, Siddiqui, Javed, Sadis, Seth, Bandla, Santhoshi, Williams, Paul D, Cho, Kathleen R, Rhodes, Daniel R, Tomlins, Scott A
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Carcinoma, Squamous Cell - genetics; Carcinoma, Squamous Cell - mortality; Carcinoma, Squamous Cell - virology; Cyclin-Dependent Kinase 4 - genetics; Disease-Free Survival; DNA Mutational Analysis; Gene Amplification; Genes, erbB-1 - genetics; Genomics; High-Throughput Nucleotide Sequencing; Human papillomavirus; Humans; Immunohistochemistry; Kaplan-Meier Estimate; Male; Middle Aged; Multiplex Polymerase Chain Reaction; Papillomavirus Infections - complications; Papillomavirus Infections - epidemiology; Penile Neoplasms - genetics; Penile Neoplasms - mortality; Penile Neoplasms - virology; Retrospective Studies; Transcriptome
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.CAN-15-1004

Penile squamous cell carcinoma (PeSCCA) is a rare malignancy for which there are limited treatment options due to a poor understanding of the molecular alterations underlying disease development and progression. Therefore, we performed comprehensive, targeted next-generation sequencing to identify relevant somatic genomic alterations in a retrospective cohort of 60 fixed tumor samples from 43 PeSCCA cases (including 14 matched primary/metastasis pairs). We identified a median of two relevant somatic mutations and one high-level copy-number alteration per sample (range, 0-5 and 0-6, respectively). Expression of HPV and p16 was detectable in 12% and 28% of patients, respectively. Furthermore, advanced clinical stage, lack of p16 expression, and MYC and CCND1 amplifications were significantly associated with shorter time to progression or PeSCCA-specific survival. Notably, four cases harbored EGFR amplifications and one demonstrated CDK4 amplification, genes for which approved and investigational targeted therapies are available. Importantly, although paired primary tumors and lymph node metastases were largely homogeneous for relevant somatic mutations, we identified heterogeneous EGFR amplification in primary tumor/lymph node metastases in 4 of 14 cases, despite uniform EGFR protein overexpression. Likewise, activating HRAS mutations occurred in 8 of 43 cases. Taken together, we provide the first comprehensive molecular PeSCCA analysis, which offers new insight into potential precision medicine approaches for this disease, including strategies targeting EGFR.